{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:20:04Z","timestamp":1791976804306,"version":"4.4.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fujian Natural Science Foundation project","award":["2022J011037"],"award-info":[{"award-number":["2022J011037"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-24217-y","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T14:47:15Z","timestamp":1763477235000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A pharmacovigilance study of daptomycin use in infants under 1 year old based on the FDA adverse event reporting system"],"prefix":"10.1038","volume":"15","author":[{"given":"Lingling","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guimu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"24217_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkx349","volume":"73","author":"M Heidary","year":"2018","unstructured":"Heidary, M. et al. Daptomycin. J. Antimicrob. Chemother. 73, 1\u201311 (2018).","journal-title":"J. Antimicrob. Chemother."},{"issue":"Suppl 3","key":"24217_CR2","first-page":"iii7","volume":"62","author":"PM Hawkey","year":"2008","unstructured":"Hawkey, P. M. Pre-clinical experience with daptomycin. J. Antimicrob. Chemother. 62 (Suppl 3), iii7\u201314 (2008).","journal-title":"J. Antimicrob. Chemother."},{"key":"24217_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1586\/14787210.5.2.177","volume":"5","author":"ZA Kanafani","year":"2007","unstructured":"Kanafani, Z. A. & Corey, G. R. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections. Expert Rev. anti-infective Therapy. 5, 177\u2013184 (2007).","journal-title":"Expert Rev. anti-infective Therapy"},{"key":"24217_CR4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ijantimicag.2014.01.018","volume":"43","author":"HS Sader","year":"2014","unstructured":"Sader, H. S., Farrell, D. J., Flamm, R. K. & Jones, R. N. Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a worldwide surveillance programme (2005\u20132012). Int. J. Antimicrob. Agents. 43, 465\u2013469 (2014).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"24217_CR5","doi-asserted-by":"crossref","unstructured":"Streit, J. M., Jones, R. N. & Sader, H. S. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. The J. Antimicrob. Chemotherapy 53, 2369 (2004).","DOI":"10.1093\/jac\/dkh143"},{"key":"24217_CR6","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jiac.2021.11.019","volume":"28","author":"S Iwata","year":"2022","unstructured":"Iwata, S., Koyama, H. & Murata, Y. Efficacy and safety of daptomycin in Japanese pediatric participants with complicated skin and soft tissue infections or bacteremia caused by gram-positive Cocci. J. Infect. Chemotherapy: Official J. Japan Soc. Chemother. 28, 406\u2013412 (2022).","journal-title":"J. Infect. Chemotherapy: Official J. Japan Soc. Chemother."},{"key":"24217_CR7","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1097\/INF.0000000000000907","volume":"34","author":"E Cobos-Carrascosa","year":"2015","unstructured":"Cobos-Carrascosa, E. et al. Staphylococcus aureus bacteremia in children: changes during eighteen years. Pediatr. Infect. Dis. J. 34, 1329\u20131334 (2015).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"24217_CR8","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/cid\/ciy1030","volume":"69","author":"AB Spaulding","year":"2019","unstructured":"Spaulding, A. B. et al. Epidemiology of bloodstream infections in hospitalized children in the united States, 2009\u20132016. Clin. Infect. Diseases: Official Publication Infect. Dis. Soc. Am. 69, 995\u20131002 (2019).","journal-title":"Clin. Infect. Diseases: Official Publication Infect. Dis. Soc. Am."},{"key":"24217_CR9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1097\/INF.0000000000003597","volume":"41","author":"CG Carvalhaes","year":"2022","unstructured":"Carvalhaes, C. G. et al. Activity of tedizolid and comparator agents against Gram-positive isolates causing skin and skin structure infections in pediatric patients in united States hospitals (2015\u20132019). Pediatr. Infect. Dis. J. 41, 731\u2013735 (2022).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"24217_CR10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/INF.0b013e318160edfc","volume":"27","author":"SM Abdel-Rahman","year":"2008","unstructured":"Abdel-Rahman, S. M. et al. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr. Infect. Dis. J. 27, 330\u2013334 (2008).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"24217_CR11","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/INF.0000000000000318","volume":"33","author":"JS Bradley","year":"2014","unstructured":"Bradley, J. S., Benziger, D., Bokesch, P. & Jacobs, R. Single-dose pharmacokinetics of daptomycin in pediatric patients 3\u201324 months of age. Pediatr. Infect. Dis. J. 33, 936\u2013939 (2014).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"24217_CR12","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1097\/INF.0b013e31825d2fa2","volume":"31","author":"M Cohen-Wolkowiez","year":"2012","unstructured":"Cohen-Wolkowiez, M., Watt, K. M., Hornik, C. P., Benjamin, D. K. Jr. & Smith, P. B. Pharmacokinetics and tolerability of single-dose daptomycin in young infants. Pediatr. Infect. Dis. J. 31, 935\u2013937 (2012).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"24217_CR13","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jiac.2023.02.012","volume":"29","author":"M Ishii","year":"2023","unstructured":"Ishii, M., Orito, Y., Shiomi, M., Wrishko, R. E. & Yoshitsugu, H. Pharmacokinetics of intravenous daptomycin in Japanese pediatric patients: pharmacokinetic comparisons supporting dosing recommendations in Japanese pediatric patients. J. Infect. Chemotherapy: Official J. Japan Soc. Chemother. 29, 592\u2013598 (2023).","journal-title":"J. Infect. Chemotherapy: Official J. Japan Soc. Chemother."},{"key":"24217_CR14","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1093\/jac\/dkae324","volume":"79","author":"C Maurille","year":"2024","unstructured":"Maurille, C. et al. Pharmacokinetics and safety of daptomycin administered subcutaneously in healthy volunteers: a single-blinded randomized crossover trial. J. Antimicrob. Chemother. 79, 3016\u20133022 (2024).","journal-title":"J. Antimicrob. Chemother."},{"key":"24217_CR15","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/jcph.2425","volume":"64","author":"KB Olney","year":"2024","unstructured":"Olney, K. B., Howard, J. I. & Burgess, D. S. Daptomycin dose optimization in pediatric Staphylococcus aureus bacteremia: a Pharmacokinetic\/Pharmacodynamic investigation. J. Clin. Pharmacol. 64, 860\u2013865 (2024).","journal-title":"J. Clin. Pharmacol."},{"key":"24217_CR16","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/clpt.2008.208","volume":"85","author":"Y Zhang","year":"2009","unstructured":"Zhang, Y. et al. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin. Pharmacol. Ther. 85, 305\u2013311 (2009).","journal-title":"Clin. Pharmacol. Ther."},{"key":"24217_CR17","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1517\/13543784.8.8.1223","volume":"8","author":"FP Tally","year":"1999","unstructured":"Tally, F. P. et al. Daptomycin: a novel agent for Gram-positive infections. Expert Opin. Investig. Drugs. 8, 1223\u20131238 (1999).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"24217_CR18","doi-asserted-by":"crossref","unstructured":"Persha, H. et al. Real-World clinical characteristics and outcomes with daptomycin use in pediatric patients: a retrospective case series. Antibiotics (Basel Switzerland) 13, 4526 (2024).","DOI":"10.3390\/antibiotics13090833"},{"key":"24217_CR19","first-page":"92","volume":"26","author":"SS Asfour","year":"2021","unstructured":"Asfour, S. S., Asfour, R. S., Khalil, T. M. & Al-Mouqdad, M. M. The use of daptomycin in the treatment of persistent Coagulase-Negative Staphylococcal sepsis in premature infants: a case series. J. Pediatr. Pharmacol. Therapeutics: JPPT : Official J. PPAG. 26, 92\u201398 (2021).","journal-title":"J. Pediatr. Pharmacol. Therapeutics: JPPT : Official J. PPAG"},{"key":"24217_CR20","doi-asserted-by":"crossref","unstructured":"Mohzari, Y. et al. Safety and efficacy of daptomycin in neonates with Coagulase-Negative staphylococci: case series analysis. Antibiotics (Basel Switzerland) 10, 1452 (2021).","DOI":"10.3390\/antibiotics10020168"},{"key":"24217_CR21","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T., Tamon, A., Kadoyama, K. & Okuno, Y. Data mining of the public version of the FDA adverse event reporting system. Int. J. Med. Sci. 10, 796\u2013803 (2013).","journal-title":"Int. J. Med. Sci."},{"key":"24217_CR22","unstructured":"Administration, U. S. F. & a., D. FDA Adverse Event Reporting System (FAERS) Public Dashboard  (2023). https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard."},{"key":"24217_CR23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7150\/ijms.7967","volume":"11","author":"T Sakaeda","year":"2014","unstructured":"Sakaeda, T., Kadoyama, K., Minami, K. & Okuno, Y. Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms. Int. J. Med. Sci. 11, 461\u2013465 (2014).","journal-title":"Int. J. Med. Sci."},{"key":"24217_CR24","doi-asserted-by":"publisher","first-page":"111128","DOI":"10.1016\/j.pnpbp.2024.111128","volume":"135","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y., Fei, L. & Duan, Y. Movement disorders related to antidiabetic medications: a real-world pharmacovigilance study. Prog. Neuro-psychopharmacol. Biol. Psychiatry. 135, 111128 (2024).","journal-title":"Prog. Neuro-psychopharmacol. Biol. Psychiatry"},{"key":"24217_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jad.2024.08.161","volume":"367","author":"Z Wang","year":"2024","unstructured":"Wang, Z. et al. Exploring the correlation between cardiovascular adverse events and antidepressant use: a retrospective pharmacovigilance analysis based on the FDA adverse event reporting system database. J. Affect. Disord. 367, 96\u2013108 (2024).","journal-title":"J. Affect. Disord."},{"key":"24217_CR26","doi-asserted-by":"publisher","first-page":"102827","DOI":"10.1016\/j.ctrv.2024.102827","volume":"130","author":"M Hua","year":"2024","unstructured":"Hua, M. et al. Abemaciclib increases the risk of venous thromboembolism in breast cancer: integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation. Cancer Treat. Rev. 130, 102827 (2024).","journal-title":"Cancer Treat. Rev."},{"key":"24217_CR27","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.cgh.2017.11.025","volume":"16","author":"V Chedid","year":"2018","unstructured":"Chedid, V., Vijayvargiya, P. & Camilleri, M. Advantages and limitations of the federal adverse events reporting system in assessing adverse event reporting for Eluxadoline. Clin. Gastroenterol. Hepatol.: Off. Clin. Pract. J. Am. Gastroenterol. Assoc.  16, 336\u2013338 (2018).","journal-title":"Clin. Gastroenterol. Hepatol.: Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"24217_CR28","doi-asserted-by":"publisher","first-page":"107058","DOI":"10.1016\/j.ejps.2025.107058","volume":"208","author":"L Ye","year":"2025","unstructured":"Ye, L., Zhou, H., Guo, G., Chen, M. & Zhang, J. Physiologically-based Pharmacokinetic modeling to predict the exposure and to assess pharmacodynamics of daptomycin in infants within 1 year old. Eur. J. Pharm. Sciences: Official J. Eur. Federation Pharm. Sci. 208, 107058 (2025).","journal-title":"Eur. J. Pharm. Sciences: Official J. Eur. Federation Pharm. Sci."},{"key":"24217_CR29","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/14740338.2024.2368817","volume":"23","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli, M., Raschi, E., Poluzzi, E. & Hauben, M. The evolving role of disproportionality analysis in pharmacovigilance. Exp. Opin. Drug Saf. 23, 981\u2013994 (2024).","journal-title":"Exp. Opin. Drug Saf."},{"key":"24217_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00002018-200326030-00003","volume":"26","author":"M Hauben","year":"2003","unstructured":"Hauben, M. & Zhou, X. Quantitative methods in pharmacovigilance: focus on signal detection. Drug Saf. 26, 159\u2013186 (2003).","journal-title":"Drug Saf."},{"key":"24217_CR31","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/pds.2014","volume":"19","author":"N Ooba","year":"2010","unstructured":"Ooba, N. & Kubota, K. Selected control events and reporting odds ratio in signal detection methodology. Pharmacoepidemiol. Drug Saf. 19, 1159\u20131165 (2010).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"24217_CR32","doi-asserted-by":"crossref","unstructured":"Rallis, D. et al. Molecular epidemiology clinical Manifestations, decolonization Strategies, and treatment options of Methicillin-Resistant Staphylococcus aureus infection in neonates. Pathogens (Basel Switzerland) 14, 4523 (2025).","DOI":"10.3390\/pathogens14020155"},{"key":"24217_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000488582","volume":"114","author":"Y Dong","year":"2018","unstructured":"Dong, Y., Glaser, K. & Speer, C. P. New threats from an old foe: Methicillin-Resistant Staphylococcus aureus infections in neonates. Neonatology 114, 127\u2013134 (2018).","journal-title":"Neonatology"},{"key":"24217_CR34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4037\/ajcc2023155","volume":"32","author":"J Ward","year":"2023","unstructured":"Ward, J. et al. Bloodstream infections in infants and children with congenital heart disease undergoing cardiac surgery. Am. J. Crit. Care: Official Publication Am. Association Critical-Care Nurses. 32, 157\u2013165 (2023).","journal-title":"Am. J. Crit. Care: Official Publication Am. Association Critical-Care Nurses"},{"key":"24217_CR35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1590\/S0036-46652014000100012","volume":"56","author":"I Furtado","year":"2014","unstructured":"Furtado, I. et al. Enterococcus faecium and Enterococcus faecalis in blood of newborns with suspected nosocomial infection. Rev. Inst. Med. Trop. Sao Paulo. 56, 77\u201380 (2014).","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"24217_CR36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S2352-4642(21)00305-9","volume":"6","author":"LF Hill","year":"2022","unstructured":"Hill, L. F. et al. Optimised versus standard dosing of Vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial. Lancet Child. Adolesc. Health. 6, 49\u201359 (2022).","journal-title":"Lancet Child. Adolesc. Health"},{"key":"24217_CR37","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s13063-020-4184-8","volume":"21","author":"LF Hill","year":"2020","unstructured":"Hill, L. F. et al. An optimised dosing regimen versus a standard dosing regimen of Vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial. Trials 21, 329 (2020).","journal-title":"Trials"},{"key":"24217_CR38","doi-asserted-by":"publisher","first-page":"F418","DOI":"10.1136\/adc.2007.128280","volume":"93","author":"O Plan","year":"2008","unstructured":"Plan, O. et al. Continuous-infusion Vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule. Arch. Dis. Child. Fetal Neonatal Ed. 93, F418\u2013421 (2008).","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"24217_CR39","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/phar.1442","volume":"34","author":"LD Burgess","year":"2014","unstructured":"Burgess, L. D. & Drew, R. H. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy 34, 670\u2013676 (2014).","journal-title":"Pharmacotherapy"},{"key":"24217_CR40","doi-asserted-by":"publisher","first-page":"O384","DOI":"10.1111\/1469-0691.12410","volume":"20","author":"RP Moenster","year":"2014","unstructured":"Moenster, R. P. et al. Acute renal failure associated with Vancomycin and \u03b2-lactams for the treatment of osteomyelitis in diabetics: piperacillin-tazobactam as compared with cefepime. Clin. Microbiol. Infection: Official Publication Eur. Soc. Clin. Microbiol. Infect. Dis. 20, O384\u2013389 (2014).","journal-title":"Clin. Microbiol. Infection: Official Publication Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"24217_CR41","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/jac\/dku453","volume":"70","author":"N Principi","year":"2015","unstructured":"Principi, N., Caironi, M., Venturini, F., Pani, L. & Esposito, S. Daptomycin in paediatrics: current knowledge and the need for future research. J. Antimicrob. Chemother. 70, 643\u2013648 (2015).","journal-title":"J. Antimicrob. Chemother."},{"key":"24217_CR42","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1093\/jpids\/piw048","volume":"5","author":"SA Karageorgos","year":"2016","unstructured":"Karageorgos, S. A., Miligkos, M., Dakoutrou, M. & Tsioutis, C. Clinical Effectiveness, safety Profile, and pharmacokinetics of daptomycin in pediatric patients: A systematic review. J. Pediatr. Infect. Dis. Soc. 5, 446\u2013457 (2016).","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"24217_CR43","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1177\/0091270004265646","volume":"44","author":"B Dvorchik","year":"2004","unstructured":"Dvorchik, B. & Damphousse, D. Single-dose pharmacokinetics of daptomycin in young and geriatric volunteers. J. Clin. Pharmacol. 44, 612\u2013620 (2004).","journal-title":"J. Clin. Pharmacol."},{"key":"24217_CR44","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","volume":"47","author":"BH Dvorchik","year":"2003","unstructured":"Dvorchik, B. H., Brazier, D., DeBruin, M. F. & Arbeit, R. D. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. 47, 1318\u20131323 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"key":"24217_CR45","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1086\/420818","volume":"38","author":"RD Arbeit","year":"2004","unstructured":"Arbeit, R. D., Maki, D., Tally, F. P., Campanaro, E. & Eisenstein, B. I. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Diseases: Official Publication Infect. Dis. Soc. Am. 38, 1673\u20131681 (2004).","journal-title":"Clin. Infect. Diseases: Official Publication Infect. Dis. Soc. Am."},{"key":"24217_CR46","doi-asserted-by":"crossref","unstructured":"Vonasek, B. J., Samuel, A. M., Henderson, S. L., Strayer, J. R. & Bogenschutz, M. C. Safety and treatment outcomes of infants and children treated with daptomycin: Six-Year experience from a pediatric academic medical center. Clin. Pediatrics  2024, 99228241242186 (2024).","DOI":"10.1177\/00099228241242186"},{"key":"24217_CR47","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s11096-022-01472-x","volume":"44","author":"JJ Chen","year":"2022","unstructured":"Chen, J. J., Huo, X. C., Wang, S. X., Wang, F. & Zhao, Q. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US food and drug administration adverse event reporting system. Int. J. Clin. Pharm. 44, 1351\u20131360 (2022).","journal-title":"Int. J. Clin. Pharm."},{"key":"24217_CR48","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2169\/internalmedicine.54.3397","volume":"54","author":"H Hagiya","year":"2015","unstructured":"Hagiya, H. et al. Myopathy and eosinophilic pneumonia coincidentally induced by treatment with daptomycin. Intern. Med. (Tokyo, Japan). 54, 525\u2013529 (2015).","journal-title":"Intern. Med. (Tokyo, Japan)"},{"key":"24217_CR49","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40262-020-00968-x","volume":"60","author":"N Gregoire","year":"2021","unstructured":"Gregoire, N. et al. Clinical pharmacokinetics of daptomycin. Clin. Pharmacokinet. 60, 271\u2013281 (2021).","journal-title":"Clin. Pharmacokinet."},{"key":"24217_CR50","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.cbi.2004.08.004","volume":"150","author":"FB Oleson","year":"2004","unstructured":"Oleson, F. B., Berman, C. L. & Li, A. P. An evaluation of the P450 Inhibition and induction potential of daptomycin in primary human hepatocytes. Chemico-Biol. Interact. 150, 137\u2013147 (2004).","journal-title":"Chemico-Biol. Interact."},{"key":"24217_CR51","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1177\/0091270004266619","volume":"44","author":"B Dvorchik","year":"2004","unstructured":"Dvorchik, B. Moderate liver impairment has no influence on daptomycin pharmacokinetics. J. Clin. Pharmacol. 44, 715\u2013722 (2004).","journal-title":"J. Clin. Pharmacol."},{"key":"24217_CR52","doi-asserted-by":"publisher","first-page":"e00452","DOI":"10.1016\/j.idcr.2018.e00452","volume":"14","author":"A Janda","year":"2018","unstructured":"Janda, A. & Jogendra, M. R. D. A case report and literature review of daptomycin-induced liver injury. IDCases 14, e00452 (2018).","journal-title":"IDCases"},{"key":"24217_CR53","doi-asserted-by":"crossref","unstructured":"Bradley, J. et al. Daptomycin for complicated skin infections: a randomized trial. Pediatrics 139, 4523 (2017).","DOI":"10.1542\/peds.2016-2477"},{"key":"24217_CR54","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1097\/INF.0000000000002790","volume":"39","author":"JS Bradley","year":"2020","unstructured":"Bradley, J. S. et al. Daptomycin for pediatric Gram-Positive acute hematogenous osteomyelitis. Pediatr. Infect. Dis. J. 39, 814\u2013823 (2020).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"24217_CR55","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1097\/INF.0000000000001926","volume":"37","author":"AC Arrieta","year":"2018","unstructured":"Arrieta, A. C. et al. Randomized multicenter study comparing safety and efficacy of daptomycin versus Standard-of-care in pediatric patients with Staphylococcal bacteremia. Pediatr. Infect. Dis. J. 37, 893\u2013900 (2018).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"24217_CR56","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1128\/AAC.03157-14","volume":"58","author":"N Bohm","year":"2014","unstructured":"Bohm, N. et al. Case report and cohort analysis of drug-induced liver injury associated with daptomycin. Antimicrob. Agents Chemother. 58, 4902\u20134903 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"24217_CR57","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.drudis.2016.02.015","volume":"21","author":"M Chen","year":"2016","unstructured":"Chen, M. et al. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discovery Today. 21, 648\u2013653 (2016).","journal-title":"Drug Discovery Today"},{"key":"24217_CR58","doi-asserted-by":"crossref","unstructured":"Mihajlovic, M. & Vinken, M. Mitochondria as the target of hepatotoxicity and Drug-Induced liver injury: molecular mechanisms and detection methods. Int. J. Mol. Sci. 23, 15526 (2022).","DOI":"10.3390\/ijms23063315"},{"key":"24217_CR59","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.cld.2013.07.002","volume":"17","author":"L Yuan","year":"2013","unstructured":"Yuan, L. & Kaplowitz, N. Mechanisms of drug-induced liver injury. Clin. Liver Dis. 17, 507\u2013518 (2013). vii.","journal-title":"Clin. Liver Dis."},{"key":"24217_CR60","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","volume":"5","author":"RJ Andrade","year":"2019","unstructured":"Andrade, R. J. et al. Drug-induced liver injury. Nat. Rev. Dis. Primers 5, 58 (2019).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"24217_CR61","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jhep.2015.04.016","volume":"63","author":"M Chen","year":"2015","unstructured":"Chen, M., Suzuki, A., Borlak, J., Andrade, R. J. & Lucena, M. I. Drug-induced liver injury: interactions between drug properties and host factors. J. Hepatol. 63, 503\u2013514 (2015).","journal-title":"J. Hepatol."},{"key":"24217_CR62","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/1091581817721675","volume":"36","author":"Q Shi","year":"2017","unstructured":"Shi, Q. et al. Drug-Induced liver injury in children: clinical Observations, animal Models, and regulatory status. Int. J. Toxicol. 36, 365\u2013379 (2017).","journal-title":"Int. J. Toxicol."},{"key":"24217_CR63","doi-asserted-by":"publisher","first-page":"F144","DOI":"10.1136\/adc.2008.152454","volume":"96","author":"S Victor","year":"2011","unstructured":"Victor, S., Dickinson, H. & Turner, M. A. Plasma aminotransferase concentrations in preterm infants. Arch. Dis. Child. Fetal Neonatal Ed. 96, F144\u2013145 (2011).","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"24217_CR64","doi-asserted-by":"publisher","first-page":"81s","DOI":"10.1177\/0148607111424411","volume":"36","author":"M Rayyan","year":"2012","unstructured":"Rayyan, M., Devlieger, H., Jochum, F. & Allegaert, K. Short-term use of parenteral nutrition with a lipid emulsion containing a mixture of soybean oil, Olive oil, medium-chain triglycerides, and fish oil: a randomized double-blind study in preterm infants. JPEN J. Parenter. Enteral. Nutr. 36, 81s\u201394s (2012).","journal-title":"JPEN J. Parenter. Enteral. Nutr."},{"key":"24217_CR65","doi-asserted-by":"crossref","unstructured":"Streifel, A. C., Varley, C. D., Ham, Y., Sikka, M. K. & Lewis, J. S. 2 nd. The challenge of antibiotic selection in prosthetic joint infections due to Corynebacterium striatum: a case report. BMC Infect. Dis. 22, 290 (2022).","DOI":"10.1186\/s12879-022-07270-0"},{"key":"24217_CR66","first-page":"e29764","volume":"14","author":"Y Nishimura","year":"2022","unstructured":"Nishimura, Y. Daptomycin-Related rhabdomyolysis complicated by severe hyperkalemia and acute kidney injury. Cureus 14, e29764 (2022).","journal-title":"Cureus"},{"key":"24217_CR67","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40264-019-00873-8","volume":"43","author":"TM Patek","year":"2020","unstructured":"Patek, T. M., Teng, C., Kennedy, K. E., Alvarez, C. A. & Frei, C. R. Comparing acute kidney injury reports among antibiotics: a pharmacovigilance study of the FDA adverse event reporting system (FAERS). Drug Saf. 43, 17\u201322 (2020).","journal-title":"Drug Saf."},{"key":"24217_CR68","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/jac\/dki476","volume":"57","author":"A Kazory","year":"2006","unstructured":"Kazory, A., Dibadj, K. & Weiner, I. D. Rhabdomyolysis and acute renal failure in a patient treated with daptomycin. J. Antimicrob. Chemother. 57, 578\u2013579 (2006).","journal-title":"J. Antimicrob. Chemother."},{"key":"24217_CR69","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1345\/aph.1K579","volume":"42","author":"G Abraham","year":"2008","unstructured":"Abraham, G., Finkelberg, D. & Spooner, L. M. Daptomycin-induced acute renal and hepatic toxicity without rhabdomyolysis. Annals Pharmacotherapy. 42, 719\u2013721 (2008).","journal-title":"Annals Pharmacotherapy"},{"key":"24217_CR70","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/jac\/dkp127","volume":"63","author":"RO Odero","year":"2009","unstructured":"Odero, R. O., Cleveland, K. O. & Gelfand, M. S. Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor. J. Antimicrob. Chemother. 63, 1299\u20131300 (2009).","journal-title":"J. Antimicrob. Chemother."},{"key":"24217_CR71","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.regg.2018.05.008","volume":"53","author":"R Ram\u00edrez-Mart\u00edn","year":"2018","unstructured":"Ram\u00edrez-Mart\u00edn, R., P\u00e9rez-Rodr\u00edguez, P., Rico-Nieto, A. & Maule\u00f3n-Ladrero, C. Early onset rhabdomyolysis and acute renal failure associated with the administration of daptomycin. A case report and literature review. Revista Esp. De Geriatria Y Gerontologia. 53, 362\u2013363 (2018).","journal-title":"Revista Esp. De Geriatria Y Gerontologia"},{"key":"24217_CR72","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/bjd.12501","volume":"169","author":"SH Kardaun","year":"2013","unstructured":"Kardaun, S. H. et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br. J. Dermatol. 169, 1071\u20131080 (2013).","journal-title":"Br. J. Dermatol."},{"key":"24217_CR73","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jaad.2019.09.036","volume":"82","author":"A Soria","year":"2020","unstructured":"Soria, A. et al. Drug reaction with eosinophilia and systemic symptoms May occur within 2 weeks of drug exposure: a retrospective study. J. Am. Acad. Dermatol. 82, 606\u2013611 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"24217_CR74","doi-asserted-by":"publisher","first-page":"693e691","DOI":"10.1016\/j.jaad.2013.01.032","volume":"68","author":"Z Husain","year":"2013","unstructured":"Husain, Z., Reddy, B. Y. & Schwartz, R. A. DRESS syndrome: part I. Clinical perspectives. J. Am. Acad. Dermatol. 68, 693e691\u2013693e614 (2013). quiz 706\u2009\u2013\u2009698.","journal-title":"J. Am. Acad. Dermatol."},{"key":"24217_CR75","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/j.jaip.2023.02.035","volume":"11","author":"A Awad","year":"2023","unstructured":"Awad, A., Goh, M. S. & Trubiano, J. A. Drug reaction with eosinophilia and systemic symptoms: a systematic review. J. Allergy Clin. Immunol. Pract. 11, 1856\u20131868 (2023).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"24217_CR76","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jaip.2018.08.013","volume":"7","author":"AR Wolfson","year":"2019","unstructured":"Wolfson, A. R. et al. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome identified in the electronic health record allergy module. J. Allergy Clin. Immunol. Pract. 7, 633\u2013640 (2019).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"24217_CR77","doi-asserted-by":"crossref","unstructured":"Blumenthal, K. G., Patil, S. U. & Long, A. A. The importance of vancomycin in drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. Allergy Asthma Proc. 33, 165\u2013171  (2012).","DOI":"10.2500\/aap.2012.33.3498"},{"key":"24217_CR78","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/j.1365-2125.1991.tb03983.x","volume":"32","author":"M Pirmohamed","year":"1991","unstructured":"Pirmohamed, M. et al. Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. Br. J. Clin. Pharmacol. 32, 741\u2013749 (1991).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"24217_CR79","doi-asserted-by":"crossref","unstructured":"Musette, P. & Janela, B. New insights into drug reaction with eosinophilia and systemic symptoms pathophysiology. Front. Med. 4, 179 (2017).","DOI":"10.3389\/fmed.2017.00179"},{"key":"24217_CR80","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-021-00284-z","volume":"7","author":"JA Kellum","year":"2021","unstructured":"Kellum, J. A. et al. Acute kidney injury. Nat. Reviews Disease Primers. 7, 52 (2021).","journal-title":"Nat. Reviews Disease Primers"},{"key":"24217_CR81","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1097\/CCM.0000000000000635","volume":"42","author":"Costa","year":"2014","unstructured":"Costa, Silva, V. T., Mar\u00e7al, L. J. & Burdmann, E. A. Risk factors for Vancomycin nephrotoxicity: still a matter of debate*. Crit. Care Med. 42, 2635\u20132636 (2014).","journal-title":"Crit. Care Med."},{"key":"24217_CR82","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.kint.2020.04.020","volume":"98","author":"M Ostermann","year":"2020","unstructured":"Ostermann, M. et al. Controversies in acute kidney injury: conclusions from a kidney disease: improving global outcomes (KDIGO) conference. Kidney Int. 98, 294\u2013309 (2020).","journal-title":"Kidney Int."},{"key":"24217_CR83","first-page":"65","volume":"25","author":"SS Asfour","year":"2021","unstructured":"Asfour, S. S., Aljobair, F., Abdelrahim, A. & Al-Mouqdad, M. M. High Alanine aminotransaminase associated with daptomycin use in a premature infant. J. mother. child. 25, 65\u201368 (2021).","journal-title":"J. mother. child."},{"key":"24217_CR84","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/sj.jp.7211898","volume":"28","author":"M Cohen-Wolkowiez","year":"2008","unstructured":"Cohen-Wolkowiez, M., Smith, P. B., Benjamin, D. K. Jr., Fowler, V. G. Jr. & Wade, K. C. Daptomycin use in infants: report of two cases with peak and trough drug concentrations. J. Perinatology: Official J. Calif. Perinat. Association. 28, 233\u2013234 (2008).","journal-title":"J. Perinatology: Official J. Calif. Perinat. Association"},{"key":"24217_CR85","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/IDR.S3649","volume":"1","author":"CA Beneri","year":"2008","unstructured":"Beneri, C. A., Nicolau, D. P., Seiden, H. S. & Rubin, L. G. Successful treatment of a neonate with persistent vancomycin-resistant enterococcal bacteremia with a daptomycin-containing regimen. Infect. Drug Resist. 1, 9\u201311 (2008).","journal-title":"Infect. Drug Resist."},{"key":"24217_CR86","doi-asserted-by":"publisher","first-page":"e671","DOI":"10.1097\/MJT.0000000000001310","volume":"29","author":"A Gkoufa","year":"2022","unstructured":"Gkoufa, A., Goutas, D., Sakellariou, S. & Cholongitas, E. A case of Daptomycin-Induced acute cholestatic hepatic injury with fatal outcomes. Am. J. Ther. 29, e671\u2013e673 (2022).","journal-title":"Am. J. Ther."},{"key":"24217_CR87","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.pedneo.2021.03.007","volume":"62","author":"H Shigeta","year":"2021","unstructured":"Shigeta, H., Tanaka, K., Hoshina, T. & Kusuhara, K. Successful daptomycin therapy for a premature neonate with left-sided infective endocarditis caused by Staphylococcus epidermidis. Pediatr. Neonatol. 62, 456\u2013457 (2021).","journal-title":"Pediatr. Neonatol."},{"key":"24217_CR88","first-page":"68","volume":"25","author":"JI Chan","year":"2020","unstructured":"Chan, J. I., Noor, A., Clauss, C., Aggarwal, R. & Nayak, A. Methicillin-Resistant Staphylococcus aureus endovascular infection in a neonate: prolonged, Safe, and effective use of daptomycin and Enoxaparin. J. Pediatr. Pharmacol. Therapeutics: JPPT : Official J. PPAG. 25, 68\u201374 (2020).","journal-title":"J. Pediatr. Pharmacol. Therapeutics: JPPT : Official J. PPAG"},{"key":"24217_CR89","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1097\/INF.0000000000001629","volume":"36","author":"GA Syrogiannopoulos","year":"2017","unstructured":"Syrogiannopoulos, G. A., Michoula, A. N., Petinaki, E. & Grivea, I. N. Daptomycin use in children: experience with various types of infection and age groups. Pediatr. Infect. Dis. J. 36, 962\u2013966 (2017).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"24217_CR90","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s15010-011-0240-3","volume":"40","author":"C Antachopoulos","year":"2012","unstructured":"Antachopoulos, C. et al. Serum levels of daptomycin in pediatric patients. Infection 40, 367\u2013371 (2012).","journal-title":"Infection"},{"key":"24217_CR91","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1097\/INF.0b013e31814523f8","volume":"26","author":"MI Ardura","year":"2007","unstructured":"Ardura, M. I. et al. Daptomycin therapy for invasive Gram-positive bacterial infections in children. Pediatr. Infect. Dis. J. 26, 1128\u20131132 (2007).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"24217_CR92","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1099\/jmm.0.027235-0","volume":"60","author":"A Hussain","year":"2011","unstructured":"Hussain, A., Kairamkonda, V. & Jenkins, D. R. Successful treatment of meticillin-resistant Staphylococcus aureus bacteraemia in a neonate using daptomycin. J. Med. Microbiol. 60, 381\u2013383 (2011).","journal-title":"J. Med. Microbiol."},{"key":"24217_CR93","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1097\/INF.0b013e31820fc8e1","volume":"30","author":"SM Abdel-Rahman","year":"2011","unstructured":"Abdel-Rahman, S. M. et al. Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10\u00a0mg\/kg in children aged 2 to 6 years with suspected or proved Gram-positive infections. Pediatr. Infect. Dis. J. 30, 712\u2013714 (2011).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"24217_CR94","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.1128\/AAC.00038-12","volume":"56","author":"I Byren","year":"2012","unstructured":"Byren, I. et al. Randomized controlled trial of the safety and efficacy of daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty. Antimicrob. Agents Chemother. 56, 5626\u20135632 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"24217_CR95","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa053783","volume":"355","author":"VG Fowler Jr","year":"2006","unstructured":"Fowler, V. G. Jr. et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355, 653\u2013665 (2006).","journal-title":"N. Engl. J. Med."},{"key":"24217_CR96","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41390-019-0526-1","volume":"86","author":"N Marlow","year":"2019","unstructured":"Marlow, N. et al. Assessment of long-term neurodevelopmental outcome following trials of medicinal products in newborn infants. Pediatr. Res. 86, 567\u2013572 (2019).","journal-title":"Pediatr. Res."},{"key":"24217_CR97","doi-asserted-by":"crossref","unstructured":"Marlow, N. Measuring neurodevelopmental outcome in neonatal trials: a continuing and increasing challenge. Arch. Dis. Childhood Fetal Neonatal Ed. 98, F554-558  (2013).","DOI":"10.1136\/archdischild-2012-302970"},{"key":"24217_CR98","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s11095-021-03058-0","volume":"38","author":"M Samura","year":"2021","unstructured":"Samura, M. et al. Population Pharmacokinetic analysis and dosing optimization based on unbound daptomycin concentration and Cystatin C in Nonobese elderly patients with hypoalbuminemia and chronic kidney disease. Pharm. Res. 38, 1041\u20131055 (2021).","journal-title":"Pharm. Res."},{"key":"24217_CR99","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/jac\/46.4.523","volume":"46","author":"FP Tally","year":"2000","unstructured":"Tally, F. P. & DeBruin, M. F. Development of daptomycin for gram-positive infections. J. Antimicrob. Chemother. 46, 523\u2013526 (2000).","journal-title":"J. Antimicrob. Chemother."},{"key":"24217_CR100","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/0018578718795271","volume":"54","author":"A Kumar","year":"2019","unstructured":"Kumar, A. The newly available FAERS public dashboard: implications for health care professionals. Hosp. Pharm. 54, 75\u201377 (2019).","journal-title":"Hosp. Pharm."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24217-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24217-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24217-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T16:03:35Z","timestamp":1763481815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24217-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":100,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24217"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-24217-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40632"}}